We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 340.85%
This Fund
S&P 500
This Quarter Est. Return
-5.38%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$530M
AUM Growth
+$88.9M
Cap. Flow
+$121M
Cap. Flow %
22.77%
Top 10 Hldgs %
58.16%
Holding
331
New
70
Increased
91
Reduced
51
Closed
65

Top Buys

Rank Stock Value
1
CYTK icon
Cytokinetics
CYTK
+$32.3M
2
PTGX icon
Protagonist Therapeutics
PTGX
+$24M
3
BBIO icon
BridgeBio Pharma
BBIO
+$19.5M
4
ROIV icon
Roivant Sciences
ROIV
+$14.9M
5
RPRX icon
Royalty Pharma
RPRX
+$12.8M

Top Sells

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$28.1M
2
MACK
Merrimack Pharmaceuticals, Inc.
MACK
+$13.3M
3
EDR
Endeavor Group Holdings, Inc.
EDR
+$3.85M
4
FUSN
Fusion Pharmaceuticals Inc. Common Shares
FUSN
+$3.78M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$3.42M

Sector Composition

Rank Sector Weight
1 Healthcare 80.42%
2 Financials 1.75%
3 Industrials 0.22%
4 Utilities 0.17%
5 Technology 0.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NNAGU
176
DELISTED
99 Acquisition Group Inc Unit
NNAGU
$80.5K 0.02%
7,500
– –
AITRU
177
DELISTED
AI Transportation Acquisition Corp Unit
AITRU
$78.8K 0.01%
7,500
– –
ADVM
178
DELISTED
Adverum Biotechnologies
ADVM
$77.5K 0.01%
11,300
+8,500
+304% +$79K
IMA
179
ImageneBio Inc
IMA
$65.4M
$77K 0.01%
3,890
+973
+33% +$17.2K
LGND icon
180
Ligand Pharmaceuticals
LGND
$6.08B
$75K 0.01%
890
-25,910
-97% -$2.06M
NRIX icon
181
Nurix Therapeutics
NRIX
$2.6B
$73K 0.01%
3,500
-32,108
-90% -$500K
IONS icon
182
Ionis Pharmaceuticals
IONS
$9.09B
$71.5K 0.01%
1,500
-1,400
-48% -$57.4K
QNCX icon
183
Quince Therapeutics
QNCX
$28.4M
$69.7K 0.01%
465
+331
+247% +$59.8K
HHH icon
184
Howard Hughes
HHH
$3.91B
$64.8K 0.01%
1,049
– –
MITK icon
185
Mitek Systems
MITK
$798M
$62.6K 0.01%
5,600
– –
GPCR icon
186
Structure Therapeutics
GPCR
$3.59B
$59.5K 0.01%
1,516
-984
-39% -$40.4K
OGN icon
187
Organon & Co
OGN
$3.56B
$51.8K 0.01%
2,500
-3,500
-58% -$69.6K
UCTT
188
Ultra Clean Holdings
UCTT
$3.79B
$49K 0.01%
1,000
– –
KSS icon
189
Kohl's
KSS
$2.29B
$46K 0.01%
2,000
– –
NGNE icon
190
Neurogene
NGNE
$704M
$45.6K 0.01%
1,253
+592
+90% +$20.9K
CASI
191
DELISTED
CASI Pharmaceuticals
CASI
$45.3K 0.01%
+8,240
New +$25.6K
EVO icon
192
Evotec
EVO
$700M
$45.1K 0.01%
9,400
+1,700
+22% +$9.53K
ETNB
193
DELISTED
89bio
ETNB
$44.5K 0.01%
5,560
+2,500
+82% +$22.3K
SVRA icon
194
PUT
Savara
SVRA
$1.11B
$44.3K 0.01%
+11,000
New +$48.9K
FDMT icon
195
4D Molecular Therapeutics
FDMT
$536M
$42K 0.01%
2,000
– –
TVRD
196
Tvardi Therapeutics
TVRD
$17.8M
$41.1K 0.01%
+4,430
New +$106K
VERA icon
197
Vera Therapeutics
VERA
$2.19B
$39K 0.01%
+1,079
New +$42.8K
CBIO
198
Crescent Biopharma
CBIO
$601M
$38K 0.01%
+1,350
New +$140K
CBIO
199
PUT
Crescent Biopharma
CBIO
$601M
$38K 0.01%
1,350
-41
-3% -$4.26K
PHVS icon
200
Pharvaris
PHVS
$2.37B
$37.6K 0.01%
2,000
– –
6 7
8
9 10

Similar funds

RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
FDP
Financiere des Professionnels Montreal, Quebec, Canada $1.71B AUM 21.77% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return

ADAR1 Capital Management's Q2 2024 Portfolio in Review

As of Q2 2024, ADAR1 Capital Management held 331 positions worth $530M, up 20% from $441M the previous quarter. Its ten largest holdings account for 58% of the portfolio.

ADAR1 Capital Management deployed $121M of net new capital in Q2 2024, opening 70 new positions and adding to 91 existing holdings. Its largest new stake was Perceptive Capital Solutions: 750,000 shares worth $7.54M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, up from 69% a quarter earlier, followed by Financials and Industrials.

On the sell side, the largest reduction was Alnylam Pharmaceuticals, an estimated $28.1M trimmed.

  • ADAR1 Capital Management's largest Q2 2024 buy was Perceptive Capital Solutions: 750,000 shares worth $7.54M.
  • ADAR1 Capital Management added most to Cytokinetics in Q2 2024, an estimated $32.3M increase.
  • ADAR1 Capital Management's biggest Q2 2024 reduction was Alnylam Pharmaceuticals, cutting an estimated $28.1M.
  • ADAR1 Capital Management fully exited Merrimack Pharmaceuticals, Inc. in Q2 2024, selling an estimated $13.3M.
  • ADAR1 Capital Management's ten largest holdings make up 58% of its $530M portfolio in Q2 2024.
  • ADAR1 Capital Management opened 70 new positions and closed 65 in Q2 2024.
  • ADAR1 Capital Management's portfolio value rose 20% quarter-over-quarter to $530M.

Based on ADAR1 Capital Management's 13F filing for Q2 2024, filed 13 Aug 2024.